Narumi Nakagiri
Stock Analyst at Daiwa Capital
(0.29)
# 4,087
Out of 4,761 analysts
10
Total ratings
20%
Success rate
-11.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Narumi Nakagiri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Upgrades: Buy | $120 → $154 | $94.20 | +63.48% | 1 | Aug 16, 2024 | |
| PFE Pfizer | Upgrades: Outperform | $28 → $34 | $26.30 | +29.28% | 3 | Aug 8, 2024 | |
| JNJ Johnson & Johnson | Downgrades: Neutral | $160 → $150 | $162.30 | -7.58% | 1 | Jul 23, 2024 | |
| AMGN Amgen | Upgrades: Buy | $320 | $303.01 | +5.61% | 2 | Dec 21, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $54 | $55.83 | -3.28% | 1 | Nov 2, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $89 → $102 | $89.50 | +13.97% | 2 | Jul 7, 2022 |
Illumina
Aug 16, 2024
Upgrades: Buy
Price Target: $120 → $154
Current: $94.20
Upside: +63.48%
Pfizer
Aug 8, 2024
Upgrades: Outperform
Price Target: $28 → $34
Current: $26.30
Upside: +29.28%
Johnson & Johnson
Jul 23, 2024
Downgrades: Neutral
Price Target: $160 → $150
Current: $162.30
Upside: -7.58%
Amgen
Dec 21, 2023
Upgrades: Buy
Price Target: $320
Current: $303.01
Upside: +5.61%
Bristol-Myers Squibb Company
Nov 2, 2023
Downgrades: Neutral
Price Target: $68 → $54
Current: $55.83
Upside: -3.28%
Merck & Co.
Jul 7, 2022
Upgrades: Outperform
Price Target: $89 → $102
Current: $89.50
Upside: +13.97%